Options for Patients with Mantle Cell Lymphoma Are 'Exploding', Expert Says
“It really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate,” said Dr. Lori A. Leslie.
Mantle cell lymphoma (MCL) is a rare, typically aggressive form of non-Hodgkin lymphoma (NHL) that accounts for approximately 6% of all new cases of NHL in the United States in a given year. But thanks to a research boom in the treatment of the disease, “outcomes are getting better all the time”, according to Dr. Lori A. Leslie.
In an interview with OncLive®, CURE®’s sister publication, Leslie, an oncologist with the John Theurer Cancer Center, explained that because of this rapid expansion, much of the older information patients have access to is outdated and not indicative of the current treatment landscape.
Transcription:
When I meet patients with mantle cell lymphoma, whether I'm meeting them first when diagnosed or (if they’re) relapsed/refractory, they've read a lot of information whether it's studies or on the internet, and I just like to highlight the research is literally exploding. Outcomes are getting better all the time. So, a lot of what you're reading about from a few years ago is dismal in some situations, and really not relevant to the current treatment landscape.
So, I am very hopeful as my career goes on, we will continue to improve treatments for mantle cell and it really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate.
Get more news and updates on mantle cell lymphoma here.
